

CONTACT  
040 6761 1600 / 6761 1700  
neuland@neulandlabs.com  
neulandlabs.com

September 23, 2025

To

**BSE Limited**

Phiroze Jeejeebhoy Towers, 25<sup>th</sup> Floor, Dalal  
Street, Mumbai – 400 001

**The National Stock Exchange of India Ltd**

Exchange Plaza,  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 001

**Scrip Code: 524558**

**Scrip Code: NEULANLAB; Series: EQ**

Dear Sir/Madam,

**Sub: Outcome of Board Meeting – Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 ("SEBI Listing Regulations")**

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Board of Directors of the Company, at their meeting held today, i.e., September 23, 2025, basis the recommendation of the Nomination and Remuneration Committee and subject to the approval of the shareholders of the Company, has approved modifications to the roles and responsibilities of the Executive Leadership, **effective April 1, 2026**. These changes are intended to align with the organisation's growth plans and to ensure a balanced focus on both short-term and long-term objectives.

- **Mr. Sucheth Rao Davuluri**, currently Vice Chairman & CEO, will be re-designated as **Executive Vice Chairman**. In his current role, Mr. Sucheth Davuluri has been driving a significant part of the day-to-day operations and has played a crucial role in helping the organisation become a strong, quality-focused API company, helping Neuland diversify from a generic API to a specialty API plus CDMO player. In this new role, Mr. Sucheth Davuluri will focus on strategic areas including long-term planning, enterprise risk management, stakeholder management, internal audit oversight, and CSR/philanthropic initiatives through Neuland Foundation.
- **Mr. Saharsh Rao Davuluri**, currently Vice Chairman & Managing Director, will be re-designated as **CEO & Managing Director**. In his current role, Mr. Saharsh Rao has helped build the CMS business elevating Neuland to a reputed CDMO. Mr. Saharsh Rao will assume responsibility for day-to-day operations, leveraging his experience in building the CMS business and understanding of client and market needs. This change will help the organization better fulfil the Company's commitments and maintain the trust of and goodwill with customers.

- A transition period shall commence with immediate effect and continue until March 31, 2026, to ensure a seamless transition of operational responsibilities. Upon completion of this period, effective April 1, 2026, the transition will be deemed complete and the changes in roles and responsibilities will become formal, subject to the approval of the shareholders.
- Both Mr. Sucheth Davuluri and Mr. Saharsh Davuluri will continue to report directly to the Executive Chairman, Dr. D. R. Rao.

This is for your information and records.

Thanking you,

Yours faithfully,  
For **Neuland Laboratories Limited**

**Sarada Bhamidipati**  
**Company Secretary**